First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer

被引：0
|
作者：
Perez, Cesar Augusto
Henry, Jason Timothy
Varkaris, Andreas
Subbiah, Vivek
Spira, Alexander I.
Schmidt, Oleg
Shen, Jinshan
Guo, Wei
Hunter, Tamieka
Jen, Kai Yu
Padval, Mahesh
Karanovic, Djuro
Wolf, Beni B.
Hamilton, Erika P.
机构：
[1] Florida Canc Specialists, Sarah Cannon Res Inst, Orlando, FL USA
[2] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[5] Virginia Canc Specialist, Fairfax, VA USA
[6] Relay Therapeut, Cambridge, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1124
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors
    Juric, Dejan
    Kalinsky, Kevin
    Oliveira, Mafalda
    Cervantes, Andres
    Bedard, Philippe
    Krop, Ian
    Hamilton, Erika
    Schmid, Peter
    Varga, Andrea
    Turner, Nick
    Italiano, Antoine
    Saura, Cristina
    Gambardella, Valentina
    Veitch, Zachary
    Dickmann, Leslie
    Kotani, Naoki
    Fredrickson, Jill
    Kapp, Amy
    Hutchinson, Katie
    Royer-Joo, Stephanie
    Vaze, Anjali
    Schutzman, Jennifer
    Jhaveri, Komal
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [42] A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2-advanced breast cancer
    Wu, Jiong
    Zhang, Jian
    Li, Man
    Cai, Li
    Sun, Tao
    Ouyang, Quchang
    Meng, Yanchun
    Shi, Yehui
    Wang, Chuan
    Liu, Qiang
    Lu, Yongkui
    Yin, Yongmei
    Chen, Qianjun
    Chen, Lilin
    Wang, Haitao
    Cui, Jiuwei
    Liao, Ning
    Wang, Shubin
    Tu, Yi
    Yan, Min
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Jordi Rodon
    Alejandro Pérez-Fidalgo
    Ian E. Krop
    Howard Burris
    Angel Guerrero-Zotano
    Carolyn D. Britten
    Carlos Becerra
    Jan Schellens
    Donald A. Richards
    Martin Schuler
    Maysa Abu-Khalaf
    Faye M. Johnson
    Malcolm Ranson
    Jeff Edenfield
    Antonio P. Silva
    Wolfgang Hackl
    Cornelia Quadt
    David Demanse
    Vincent Duval
    Jose Baselga
    [J]. Cancer Chemotherapy and Pharmacology, 2018, 82 : 285 - 298
  • [44] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Rodon, Jordi
    Perez-Fidalgo, Alejandro
    Krop, Ian E.
    Burris, Howard
    Guerrero-Zotano, Angel
    Britten, Carolyn D.
    Becerra, Carlos
    Schellens, Jan
    Richards, Donald A.
    Schuler, Martin
    Abu-Khalaf, Maysa
    Johnson, Faye M.
    Ranson, Malcolm
    Edenfield, Jeff
    Silva, Antonio P.
    Hackl, Wolfgang
    Quadt, Cornelia
    Demanse, David
    Duval, Vincent
    Baselga, Jose
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 285 - 298
  • [45] First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
    Bedard, Philippe L.
    Davies, Michael A.
    Kopetz, Scott
    Flaherty, Keith T.
    Shapiro, Geoffrey
    Luke, Jason John
    Spreafico, Anna
    Wu, Bin
    Gomez, Corinne
    Cartot-Cotton, Sylvaine
    Mazuir, Florent
    Micallef, Sandrine
    Demers, Brigitte
    Juric, Dejan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics
    Shapiro, G. I.
    Molina, J.
    Bendell, J.
    Brana, I.
    Spicer, J.
    Kwak, E.
    Pandya, S.
    Millham, R.
    Houk, B.
    Bell-McGuinn, K.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 123 - 123
  • [47] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
    Shapiro, Geoffrey I.
    Bell-McGuinn, Katherine M.
    Molina, Julian R.
    Bendell, Johanna
    Spicer, James
    Kwak, Eunice L.
    Pandya, Susan S.
    Millham, Robert
    Borzillo, Gary
    Pierce, Kristen J.
    Han, Lixin
    Houk, Brett E.
    Gallo, Jorge D.
    Alsina, Maria
    Brana, Irene
    Tabernero, Josep
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1888 - 1895
  • [48] First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics
    Britten, C. D.
    Adjei, A. A.
    Millham, R.
    Houk, B.
    Wainberg, Z. A.
    Guthrie, T.
    Dy, G.
    LoRusso, P. M.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 121 - 122
  • [49] A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma
    Dolly, S.
    Wagner, A. J.
    Bendell, J. C.
    Yan, Y.
    Ware, J. A.
    Mazina, K. E.
    Holden, S. N.
    Derynck, M. K.
    De Bono, J. S.
    Burris, H. A., III
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors
    Rasco, D.
    Sullivan, R.
    Lakhani, N.
    Reddy, S.
    Rao, N.
    Denis, L.
    Tolcher, A.
    Flaherty, K. T.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345